Navigation Links
CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
Date:10/26/2007

PALO ALTO, Calif., Oct. 26 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that, in accordance with Nasdaq marketplace rule 4350, the Company issued new inducement stock options to 14 non-executive officers due to additional hiring, primarily in connection with its commercialization efforts in the United States.

The inducement stock options cover an aggregate 23,600 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options have a 10 year term and vest over four years as follows: 20 percent of these options will vest on the date one year from the optionee's hire date, 20 percent of the options will vest in monthly increments during each of the second and third years, and 40 percent of the options will vest in monthly increments during the fourth year (in all cases subject to the terms and conditions of CV Therapeutics 2004 Employment Commencement Incentive Plan).

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets) is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
3. Sonic Foundry reports GAAP loss as Q2 revenues rise
4. Fiserv reports $113.5 million in Q1 profit
5. Third Wave reports net loss of $18.9M for 2006
6. Musicnotes reports 45 percent growth in 2006
7. Sonic Foundry reports net loss, higher revenue
8. Sonic Foundry reports first cash-positive quarter
9. Merge Healthcare reports $10.8M net loss in Q3
10. Third Wave reports $5.2M third quarter loss
11. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)...  MiMedx Group, Inc. (NASDAQ: MDXG ), the ... patent-protected processes to develop and market advanced products and ... Medicine, Ophthalmic and Dental sectors of healthcare, announced today ... Annual Canaccord|Genuity Growth Conference in Boston, Massachusetts ... William C. Taylor , President and COO, and ...
(Date:8/3/2015)...  Merck KGaA, Darmstadt, Germany , ... in the healthcare, life science and performance materials sectors, ... development and launch of promising new fullerene derivatives for ... Darmstadt, Germany , is pursuing many ... Novel derivatives: highly stable, easy to process and ...
(Date:8/3/2015)... , Aug. 3, 2015  Aethlon Medical, Inc. (Nasdaq: ... to treat life-threatening diseases, today announced that it will ... and webcast on Thursday, August 13, 2015 at 4:30 ... will follow the release of fiscal 2016 first quarter ... available approximately two hours after the call at the ...
(Date:8/3/2015)... Md. , Aug. 3, 2015   Intrexon ... will release first half and second quarter 2015 financial ... th , 2015.  The Company will host a conference ... and provide a general business update. The ... US) and 1-412-902-4262 (International), and asking to join the ...
Breaking Biology Technology:MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2
... today announced that Garry W. Rogerson, President and CEO,will speak ... Thursday,December 4, 2008 at 9:45 a.m. Eastern time. , ... presentation will be publicly available from Varian,Inc.,s Web site at ... on "Investors." An archived replay will be available to ...
... Duska Therapeutics,Inc. (OTC Bulletin Board: DSKA) will host ... its drug development programs and financial results,for the third ... Kuo,MD, MBA, will host the call and there will ... To participate in the teleconference, please ...
... Nov. 20 Cyntellect, a privately-held life,sciences company ... manipulation and purification systems, announced today that it ... University of Florida ,Interdisciplinary Center for Biotechnology Research. ... research areas including the purification and analysis of,cancer ...
Cached Biology Technology:Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results 2Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results 3Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results 4Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results 5Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results 6Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results 7University of Florida and Cyntellect Collaborate to Unlock Mysteries of Cancer Stem Cells 2University of Florida and Cyntellect Collaborate to Unlock Mysteries of Cancer Stem Cells 3
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the fourth ... 2015 after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
(Date:7/8/2015)... NEW YORK , July 8, 2015 /PRNewswire/ ... today announced BD & Guidepoint Mentor, a ... access to Guidepoint,s expert network services. ... cutting-edge technologies to improve healthcare delivery and outcomes and, ... each start-up entrepreneur will be able to directly engage ...
(Date:7/7/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") a ... a revised version of one of its first 30 second commercials ... in New York , Chicago ... Francisco metro areas.    , , , ... all the cards in your wallet and keep your identity secure. ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... at the heart of a novel agricultural technique to manage ... can be used to turn carbon dioxide emissions into soil-enriching ... thrives in tropical areas, such as West Africa. ... in dry, acidic soil and treated with a combination of ...
... Researchers at the Instituto Andaluz de Ciencias de la Tierra ... was recently published in the prestigious journal Reviews of ... from 11 different countries has published the most comprehensive study ... the most important contemporary issues in a field of research ...
... Endocrine Society,s Journal of Clinical Endocrinology and Metabolism ... reduce the rate of mortality in seniors, therefore providing ... During the last decade, there has been increasing ... It is well known that calcium with vitamin D ...
Cached Biology News:Bugs have key role in farming approach to storing CO2 emissions 2Spanish scientist participate in the most comprehensive study ever done on ice 2
Mouse monoclonal [SPM325] to Xanthine Oxidase, prediluted ( Abpromise for all tested applications). Antigen: C terminal 358 amino acid fragment of human xanthine oxidase. Entrez Gene ID: 749...
Rab1A...
Drugs and NO-drug Rat Anti-conjugated Acetyl Salicylic Acid Polyclonal Antibody...
Applications: Beadlyte® assay Stability: 2 years at 4°C (lyophilized) or 6 months at -20°C (rehydrated) ...
Biology Products: